N. Thoua

发表

Prophylaxis and treatment of infective endocarditis in adults: a concise guide.

A. Thillainayagam, D. Bansi, G. Mehta, 2005, Clinical medicine.

Clinical, biomarker and endoscopic outcomes in patients with Crohn’s disease treated with Ustekinumab: Multi‐centre real world study

A. Cole, J. Segal, N. Arebi, 2021 .

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Sarah F. Griffee, Susan M. Kilroy, Philip Smith, 2022, The Lancet Gastroenterology & Hepatology.

Amitriptyline modifies the visceral hypersensitivity response to acute stress in the irritable bowel syndrome

A. Roy, C. Murray, M. A. Kamm, 2009, Alimentary pharmacology & therapeutics.

Irritable bowel syndrome

C. Murray, O. Goodkin, F. Laskaratos, 2011 .

Encephalitogenic and immunogenic potential of the stress protein αB-crystallin in Biozzi ABH (H-2Ag7) mice

P. Travers, D. Baker, S. Amor, 2000, Journal of Neuroimmunology.

Internal anal sphincter atrophy in patients with systemic sclerosis.

Alastair Forbes, Anton V Emmanuel, A. Forbes, 2011, Rheumatology.

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Susan M. Kilroy, C. Lees, T. Ahmad, 2022, Nature Communications.

Fecal Incontinence in Systemic Sclerosis Is Secondary to Neuropathy

A. Forbes, C. Denton, A. Emmanuel, 2012, The American Journal of Gastroenterology.

Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre.

A. Forbes, C. Bunce, C. Denton, 2010, Rheumatology.

Gut fibrosis with altered colonic contractility in a mouse model of scleroderma.

C. Denton, X. Shi-wen, A. Dooley, 2012, Rheumatology.

PTH-060 The role of risk stratification in predicting inflammatory bowel disease patients that require tb prophylaxis prior to biologic therapy

G. Bothamley, C. Pollock, E. Wood, 2015 .

Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis.

J. Mclaughlin, K. Chakravarty, O. Ogunbiyi, 2014, Clinical and experimental rheumatology.

Treating functional lower gastrointestinal symptoms.

A. Emmanuel, N. Thoua, 2006, Clinical medicine.

Acid‐related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non‐erosive reflux disease

D. Khoo, A. Emmanuel, N. Thoua, 2007, Alimentary pharmacology & therapeutics.